Dog Anxiety Biologics and Welfare Science

Biological treatments including monoclonal antibodies are emerging as promising tools for managing severe anxiety disorders in dogs.

Key Facts

Frunevetmab is a licensed anti-NGF monoclonal antibody for osteoarthritis pain management in dogs
Research into monoclonal antibody approaches for anxiety disorders in dogs is in early clinical stages
Biologics offer potential for more targeted and sustained treatment effects than small molecule drugs
Current anxiety medications including SSRIs and tricyclics require weeks to reach therapeutic levels
Novel treatment approaches including intranasal oxytocin and cannabis-derived compounds are under investigation

Welfare Considerations

Severe anxiety disorders in dogs represent a major welfare problem that is incompletely addressed by current pharmacological options. Emerging biological treatments may provide more effective, targeted relief for dogs with treatment-resistant anxiety. Investment in veterinary psychopharmacology research is a welfare priority given the scale of canine anxiety burden.

What You Can Do

Follow WSAVA and BSAVA guidelines on emerging pharmacological treatments for canine anxiety
Discuss current best-practice anxiety treatment options with a veterinary behaviourist
Support veterinary research charities funding novel anxiety treatment development
Advocate for regulatory frameworks that expedite approval of effective veterinary anxiety treatments